Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.

Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2012 Jan 3;106(1):61-9. doi: 10.1038/bjc.2011.526. Epub 2011 Dec 1.


Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group.

Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.


Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebski V, Zalcberg J, Simes RJ; Australasian Gastro-Intestinal Trials Group.

Eur J Cancer. 2011 Aug;47(12):1826-36. doi: 10.1016/j.ejca.2011.04.024. Epub 2011 Jun 12. Erratum in: Eur J Cancer. 2012 Feb;48(3):407.


Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.

Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ; Australasian Gastro-Intestinal Trials Group.

Ann Oncol. 2011 Aug;22(8):1834-8. doi: 10.1093/annonc/mdq702. Epub 2011 Jan 27.


Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.

Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; Australasian Gastro-Intestinal Trials Group.

Br J Cancer. 2010 Feb 2;102(3):475-81. doi: 10.1038/sj.bjc.6605522. Epub 2010 Jan 12.


A case study evaluation of ethics review systems for multicentre clinical trials.

Hicks SC, James RE, Wong N, Tebbutt NC, Wilson K; Australasian Gastro-Intestinal Trials Group.

Med J Aust. 2009 Sep 7;191(5):280-2. Review.


Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group.

Lancet Oncol. 2007 Mar;8(3):226-34.


Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group.

Lancet Oncol. 2005 Sep;6(9):659-68.


Supplemental Content

Loading ...
Support Center